A strategic plan “going beyond just cost savings” to “better capture existing and new growth opportunities,” has been developed by Fresenius Kabi’s refreshed management team, with the initial step of implementing a “business led rather than regional organization.”
Fresenius Kabi Unveils 2026 Strategy With Focus On Business Not Region
Increased Focus On Biosimilars And Peptides Under New CEO Michael Sen
Fresenius Kabi has revealed a five-year strategic roadmap, driven by its fresh management team, including broadly to increase the injectables specialist’s global competitiveness and advance organizational effectiveness.
More from Earnings
More from Business
• By
Aurobindo is set to join Lupin by competing against Johnson/Bayer’s blockbuster blood thinner Xarelto (rivaroxaban) 2.5mg tablets.
• By
Coherus has officially marked its exit from biosimilars by completing the divestment of its Udenyca pegfilgrastim franchise. Meanwhile, buyer Accord BioPharma has set out how it expects to benefit not only from a growing asset but also from the Coherus personnel that have moved over.
• By
Following past challenges on the US market, the Indian pharma player Wockhardt will be shuttering its presence in the country due to commercial reasons.